Treating Late-Stage EGFR+ Metastatic NSCLC: Monotherapy vs Intensive Combination Therapy (non-accredited)

With a growing arsenal of approved therapies for EGFR-positive metastatic non-small cell lung cancer (NSCLC), clinicians face critical decisions in tailoring treatment approaches. This session explores the nuanced considerations between classic monotherapy and intensive combination regimens in late-stage disease. Discussion will focus on how evolving clinical guidelines and real-world factors shape treatment decisions, the safety and tolerability of therapy escalation, and the balance between clinical efficacy and patient quality of life. Special attention will be given to caregiver burden and how patient-centered values—such as preferences, lifestyle, and support systems—can and should guide therapeutic strategies. Moderator: Edward Garon, MD, MS Supported by funding from AstraZeneca. All content developed independently by HMP Global.